Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone - PubMed (original) (raw)
Randomized Controlled Trial
. 2017 Nov;22(6):1528-1539.
doi: 10.1111/adb.12427. Epub 2016 Aug 2.
Affiliations
- PMID: 27480445
- PMCID: PMC5290305
- DOI: 10.1111/adb.12427
Randomized Controlled Trial
Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone
Corey R Roos et al. Addict Biol. 2017 Nov.
Abstract
Researchers have sought to distinguish between individuals whose alcohol use disorder (AUD) is maintained by drinking to relieve negative affect ('relief drinkers') and those whose AUD is maintained by the rewarding effects of alcohol ('reward drinkers'). As an opioid receptor antagonist, naltrexone may be particularly effective for reward drinkers. Acamprosate, which has been shown to down-regulate the glutamatergic system, may be particularly effective for relief drinkers. This study sought to replicate and extend prior work (PREDICT study; Glöckner-Rist et al. ) by examining dimensions of reward and relief temptation to drink and subtypes of individuals with distinct patterns of reward/relief temptation. We utilized data from two randomized clinical trials for AUD (Project MATCH, n = 1726 and COMBINE study, n = 1383). We also tested whether classes of reward/relief temptation would predict differential response to naltrexone and acamprosate in COMBINE. Results replicated prior work by identifying reward and relief temptation factors, which had excellent reliability and construct validity. Using factor mixture modeling, we identified five distinct classes of reward/relief temptation that replicated across studies. In COMBINE, we found a significant class-by-acamprosate interaction effect. Among those most likely classified in the high relief/moderate reward temptation class, individuals had better drinking outcomes if assigned to acamprosate versus placebo. We did not find a significant class-by-naltrexone interaction effect. Our study questions the orthogonal classification of drinkers into only two types (reward or relief drinkers) and adds to the body of research on moderators of acamprosate, which may inform clinical decision making in the treatment of AUD.
Keywords: Acamprosate; alcohol use disorder; naltrexone; temptation.
© 2016 Society for the Study of Addiction.
Figures
Figure 1
Standardized factor loadings for confirmatory factor analysis models of AASE temptation items. AASE = Alcohol Abstinence Self-Efficacy Scale. Arrows on far left of figure represent the residual errors. Unbolded parameters are for the COMBINE study sample. Bolded parameters are for MATCH study sample.
Figure 2
Interaction of acamprosate and latent class in predicting drinking outcomes. * = mean difference is significant at p < .05. Error bars are 95% confidence intervals.
Similar articles
- Examining a brief measure and observed cutoff scores to identify reward and relief drinking profiles: Psychometric properties and pharmacotherapy response.
Votaw VR, Mann K, Kranzler HR, Roos CR, Nakovics H, Witkiewitz K. Votaw VR, et al. Drug Alcohol Depend. 2022 Mar 1;232:109257. doi: 10.1016/j.drugalcdep.2021.109257. Epub 2021 Dec 31. Drug Alcohol Depend. 2022. PMID: 35042096 Free PMC article. - Advancing Precision Medicine for Alcohol Use Disorder: Replication and Extension of Reward Drinking as a Predictor of Naltrexone Response.
Witkiewitz K, Roos CR, Mann K, Kranzler HR. Witkiewitz K, et al. Alcohol Clin Exp Res. 2019 Nov;43(11):2395-2405. doi: 10.1111/acer.14183. Epub 2019 Sep 11. Alcohol Clin Exp Res. 2019. PMID: 31436886 Free PMC article. Clinical Trial. - Precision Medicine in Alcohol Dependence: A Controlled Trial Testing Pharmacotherapy Response Among Reward and Relief Drinking Phenotypes.
Mann K, Roos CR, Hoffmann S, Nakovics H, Leménager T, Heinz A, Witkiewitz K. Mann K, et al. Neuropsychopharmacology. 2018 Mar;43(4):891-899. doi: 10.1038/npp.2017.282. Epub 2017 Nov 20. Neuropsychopharmacology. 2018. PMID: 29154368 Free PMC article. Clinical Trial. - New pharmacotherapies for alcohol dependence.
Graham R, Wodak AD, Whelan G. Graham R, et al. Med J Aust. 2002 Jul 15;177(2):103-7. doi: 10.5694/j.1326-5377.2002.tb04683.x. Med J Aust. 2002. PMID: 12098353 Review. - Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspective.
Soyka M, Chick J. Soyka M, et al. Am J Addict. 2003;12(s1):s69-s80. doi: 10.1111/j.1521-0391.2003.tb00497.x. Am J Addict. 2003. PMID: 14972781 Review.
Cited by
- Examining a brief measure and observed cutoff scores to identify reward and relief drinking profiles: Psychometric properties and pharmacotherapy response.
Votaw VR, Mann K, Kranzler HR, Roos CR, Nakovics H, Witkiewitz K. Votaw VR, et al. Drug Alcohol Depend. 2022 Mar 1;232:109257. doi: 10.1016/j.drugalcdep.2021.109257. Epub 2021 Dec 31. Drug Alcohol Depend. 2022. PMID: 35042096 Free PMC article. - Alcohol and Pain: A Translational Review of Preclinical and Clinical Findings to Inform Future Treatment Strategies.
Edwards S, Vendruscolo LF, Gilpin NW, Wojnar M, Witkiewitz K. Edwards S, et al. Alcohol Clin Exp Res. 2020 Feb;44(2):368-383. doi: 10.1111/acer.14260. Epub 2020 Jan 6. Alcohol Clin Exp Res. 2020. PMID: 31840821 Free PMC article. Review. - Differences between treatment-seeking and non-treatment-seeking participants in medication studies for alcoholism: do they matter?
Ray LA, Bujarski S, Yardley MM, Roche DJO, Hartwell EE. Ray LA, et al. Am J Drug Alcohol Abuse. 2017 Nov;43(6):703-710. doi: 10.1080/00952990.2017.1312423. Epub 2017 Apr 20. Am J Drug Alcohol Abuse. 2017. PMID: 28426264 Free PMC article. - Kappa-opioid receptor stimulation in the nucleus accumbens shell and ethanol drinking: Differential effects by rostro-caudal location and level of drinking.
Pirino BE, Hawks A, Carpenter BA, Candelas PG, Gargiulo AT, Curtis GR, Karkhanis AN, Barson JR. Pirino BE, et al. Neuropsychopharmacology. 2024 Sep;49(10):1550-1558. doi: 10.1038/s41386-024-01850-1. Epub 2024 Mar 25. Neuropsychopharmacology. 2024. PMID: 38528134 Free PMC article. - Translational models of addiction phenotypes to advance addiction pharmacotherapy.
Ray LA, Nieto SJ, Grodin EN. Ray LA, et al. Ann N Y Acad Sci. 2023 Jan;1519(1):118-128. doi: 10.1111/nyas.14929. Epub 2022 Nov 17. Ann N Y Acad Sci. 2023. PMID: 36385614 Free PMC article. Review.
References
- Addolorato G, Abenavoli L, Leggio L, Gasbarrini G. How many cravings? Pharmacological aspects of craving treatment in alcohol addiction: a review. Neuropsychobiology. 2005;51:59–66. - PubMed
- Aiken LS, West SG. Multiple regression: Testing and interpreting interactions. Thousand Oaks: Sage; 1991.
- Annis H, Davis CS, Graham JM, Ontario . Inventory of drinking situations (IDS): User’s guide. Addiction Research Foundation; 1987.
- Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, … Longabaugh R. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295:2003–2017. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials